A 28-year-old woman with newly diagnosed pulmonary TB is started on standard first-line antitubercular therapy. She is on oral contraceptives (ethinylestradiol + levonorgestrel). After 6 weeks of therapy, she reports breakthrough bleeding and is concerned about contraceptive failure. Which antitubercular drug is responsible for this interaction, and what is the mechanism?

Explanation

## Drug–Drug Interaction: Rifampicin and Oral Contraceptives ### The Problem Breakthrough bleeding in a woman on oral contraceptives during antitubercular therapy indicates reduced contraceptive efficacy — a classic rifampicin-OCP interaction. ## Mechanism of Rifampicin-OCP Interaction **Key Point:** Rifampicin is a potent inducer of hepatic cytochrome P450 enzymes, particularly **CYP3A4**, which metabolizes both ethinylestradiol and progestins (levonorgestrel). ### Pharmacokinetic Cascade ```mermaid flowchart TD A[Rifampicin administered]:::action --> B[Induces hepatic CYP3A4 enzyme]:::outcome B --> C[Increased metabolism of ethinylestradiol + levonorgestrel]:::outcome C --> D[Reduced serum levels of OCP]:::outcome D --> E[Loss of ovulation suppression]:::urgent E --> F[Breakthrough bleeding + contraceptive failure]:::urgent ``` ### Consequences | Consequence | Details | |-------------|----------| | **Serum OCP levels** | Decreased by 30–50% | | **Ovulation suppression** | Lost; breakthrough ovulation occurs | | **Clinical signs** | Breakthrough bleeding, spotting | | **Risk** | Unintended pregnancy | | **Onset** | Usually within 2–3 weeks of starting rifampicin | | **Duration** | Persists throughout rifampicin therapy; reverses 2–3 weeks after stopping | **High-Yield:** Rifampicin is the ONLY first-line antitubercular drug with clinically significant enzyme induction. Isoniazid, pyrazinamide, and ethambutol do NOT induce CYP3A4. ## Clinical Management **Mnemonic: "RISE" — Rifampicin Interactions with Steroids & Estrogens** - **R**ifampicin is the culprit - **I**nduces CYP3A4 - **S**teroid/estrogen levels fall - **E**ffectiveness lost ### Counseling Points 1. **Increase OCP dose:** Use formulations with ≥50 µg ethinylestradiol (standard formulations are 20–35 µg). 2. **Dual contraception:** Recommend barrier methods (condoms) in addition to OCP. 3. **Alternative contraception:** Consider intrauterine devices (IUDs) or implants (not affected by enzyme induction). 4. **Timing:** Enzyme induction begins within days and is fully established by 1–2 weeks. **Clinical Pearl:** This interaction is bidirectional — OCPs do NOT significantly affect rifampicin levels, but rifampicin dramatically reduces OCP efficacy. [cite:KD Tripathi 8e Ch 48, Harrison 21e Ch 205]